MOUNTAIN VIEW, Calif., July 22, 2008 (PRIME NEWSWIRE) -- Pharsight Corporation (Nasdaq:PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that two members of its scientific consulting staff have been invited to speak to members of the biotechnology and pharmaceutical industries attending the 9th World Congress on Clinical Pharmacology and Therapeutics (CPT). The CPT Congress will be held at the Quebec City Convention Center in Quebec City, Canada, from July 27-August 1, 2008.
Rene Bruno, Ph.D., managing director, Pharsight Strategic Consulting Services, Europe, will present a case study on the use of tumor progression modeling and clinical trial simulations to predict efficacy and survival benefit of anticancer agents. Samer Mouksassi, Ph.D., associate scientist, Pharsight Reporting and Analysis Services, will present case studies on model-based analytical methods to improve drug development efficiency. Dr. Bruno and Dr. Mouksassi will both present at CPT on June 30.
* Modeling of Tumor Progression, Anticancer Drug Effect and
Simulation of Clinical Endpoints in Oncology. Dr. Bruno will
present this case study as part of a conference symposium on
applications of mechanism-based PK/PD modeling to clinical
practice. The symposium will describe research on how drug-disease
models have been used to support critical issues in trial design,
dose selection, and development strategy across a variety of
therapeutic areas.
* PK/PD Modeling, Biomarkers and Clinical Endpoints: The Use of
Cluster Analyses, Logistic Regressions, and Receiver Operator
Characteristics (ROC) for Efficient Drug Development. Dr.
Mouksassi will present as part of a poster session on methods in
clinical pharmacology. His presentation will include case studies
in several therapeutic areas illustrating how advanced statistical
methods can be combined with PK/PD modeling to provide additional
insights for the analysis of biomarkers and clinical endpoints.
"Model-based drug development has significant value for optimizing drug therapy and for improving the confidence of drug development decisions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development teams can benefit from the quantitative application of drug-disease models to simulate expected clinical responses of new therapies, such as in oncology, to support critical program strategies and enhance study design decisions. Development organizations that combine predictive drug-disease models with advanced statistical tools can derive further strategic benefits, such as early detection of response according to key biomarkers that can in turn drive optimal trial designs."
"Pharsight is pleased that experts from both of the company's scientific consulting units, Strategic Consulting Services (SCS) and Reporting and Analysis Services (RAS), will participate at this year's CPT conference," continued Shawn O'Connor. "We are committed to further enhancing the services that we provide to our clients to improve drug development productivity and decision-making, and look forward to sharing our perspective with industry colleagues on the strategic use of modeling and simulation."
Pharsight will be exhibiting its software products and scientific consulting capabilities at CPT 2008, in Booth #600. Further information can be found at www.cpt2008.com.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.